NCT/Study#
NCT05812807 /
A012103
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
DISEASE GROUP:
Breast Cancer Clinical Trials
current phase:
Unspecified
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
